Peetz Christopher 4

What Happened

• Christopher Peetz, CEO of Mirum Pharmaceuticals, had performance restricted stock units convert to common shares on March 15, 2026 (several conversion entries of 25,000 and 50,000 shares). Following the vesting/conversion, 40,985 shares were sold in the open market on March 16, 2026 at $91.98 per share, generating about $3,769,714. Separate entries show shares disposed at $0.00 for tax withholding related to the vesting.

Key Details

• Transaction dates and prices:
  • 2026-03-15: Conversion/exercise of performance RSUs (entries of 25,000 and 50,000 shares; reported as derivative exercises/conversions).
  • 2026-03-16: Open-market sale of 40,985 shares at $91.98, proceeds ≈ $3,769,714.
  • 2026-03-15: Disposals of 25,000 and 50,000 shares at $0.00 (shares withheld for tax).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each performance restricted stock unit (PRSU) converts to one share upon vesting.
  • F2: The open-market sale was to cover tax-withholding obligations tied to the PRSU vesting.
  • F3/F4: Vesting schedules cited (portions vested March 15 in 2025 and 2026, and additional vesting in 2026 and 2027) — these explain the multiple conversion entries.
• Filing timeliness: Report filed March 17, 2026 for transactions on March 15–16, 2026; appears timely under Form 4 rules.

Context

• These entries reflect PRSU vesting and routine tax-withholding activity rather than a discretionary “sell to take profits” signal. The filing shows conversion of performance awards into shares, some shares withheld for taxes (reported as $0 disposals), and an open-market sale to cover tax obligations. Such post-vesting withholding and sales are common and do not by themselves indicate the insider’s view on the company’s prospects.